Diasorin SpA (MIL:DIA) Debt-to-Equity : 0.78 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA Debt-to-Equity?

Diasorin SpA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €110 Mil. Diasorin SpA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1,083 Mil. Diasorin SpA's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €1,539 Mil. Diasorin SpA's debt to equity for the quarter that ended in Dec. 2023 was 0.78.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Diasorin SpA's Debt-to-Equity or its related term are showing as below:

MIL:DIA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 1.02
Current: 0.78

During the past 13 years, the highest Debt-to-Equity Ratio of Diasorin SpA was 1.02. The lowest was 0.00. And the median was 0.05.

MIL:DIA's Debt-to-Equity is ranked worse than
78.68% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs MIL:DIA: 0.78

Diasorin SpA Debt-to-Equity Historical Data

The historical data trend for Diasorin SpA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Debt-to-Equity Chart

Diasorin SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.02

0.89

0.78

Diasorin SpA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.89	-	-	-	0.78

Competitive Comparison of Diasorin SpA's Debt-to-Equity

For the Diagnostics & Research subindustry, Diasorin SpA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diasorin SpA's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's Debt-to-Equity falls into.

Diasorin SpA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Diasorin SpA's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(109.648	+	1083.006)	/	1538.611
	=	0.78

Diasorin SpA's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(109.648	+	1083.006)	/	1538.611
	=	0.78

Diasorin SpA (MIL:DIA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Diasorin SpA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA (MIL:DIA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (MIL:DIA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DSRLF:USA 0GZX:UK 34D:Germany

Address

Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040

Website

https://www.diasoringroup.com

Diasorin SpA is a biotechnology company engaged in developing, producing, and marketing reagent kits for laboratory diagnostics around the world. The business has focused on the immunodiagnostic market, molecular diagnostics, and Life Science sector. The company has a presence in Italy, Europe, North America, and the Rest of the world, where the majority of its revenue is from North America followed by Italy.